These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22717785)

  • 1. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics.
    Cho KJ; Kim HS; Koh JS; Kim JC
    Int Urogynecol J; 2013 Feb; 24(2):325-30. PubMed ID: 22717785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary nerve growth factor correlates with the severity of urgency and pain.
    Kim SW; Im YJ; Choi HC; Kang HJ; Kim JY; Kim JH
    Int Urogynecol J; 2014 Nov; 25(11):1561-7. PubMed ID: 24866276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention.
    Liu HT; Kuo HC
    Neurourol Urodyn; 2009; 28(1):78-81. PubMed ID: 19089891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Overactive Bladder.
    Fukui S; Aoki K; Morizawa Y; Miyake M; Fujimoto K
    Urology; 2017 May; 103():214-217. PubMed ID: 28161379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary nerve growth factor in women with overactive bladder syndrome.
    Liu HT; Chen CY; Kuo HC
    BJU Int; 2011 Mar; 107(5):799-803. PubMed ID: 20804479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of urinary nerve growth factor for the diagnosis and assessment of the biofeedback success in children with dysfunctional voiding.
    Ergin G; Kibar Y; Ebiloğlu T; Irkılata HC; Kopru B; Kaya E; Uyanık M; Tapan S; Dayanc MM
    J Pediatr Urol; 2016 Apr; 12(2):118.e1-6. PubMed ID: 26701107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
    Liu HT; Chancellor MB; Kuo HC
    BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder.
    Vijaya G; Cartwright R; Derpapas A; Gallo P; Fernando R; Khullar V
    Int Urogynecol J; 2013 Sep; 24(9):1523-8. PubMed ID: 23376905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
    Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
    BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome.
    Beta A; Giannouli A; Rizos D; Mantzou A; Deligeoroglou E; Bakas P
    Int Urogynecol J; 2024 Jun; 35(6):1317-1322. PubMed ID: 38761233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
    Aydoğmuş Y; Sunay M; Arslan H; Aydın A; Adiloğlu AK; Şahin H
    Urol Int; 2014; 93(4):437-43. PubMed ID: 25033919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.
    Ciftci S; Ozkurkcugil C; Yilmaz H; Ustuner M; Yavuz U; Yuksekkaya M; Cekmen MB
    Int Urogynecol J; 2016 Feb; 27(2):275-80. PubMed ID: 26310546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder.
    Yokoyama T; Kumon H; Nagai A
    Neurourol Urodyn; 2008; 27(5):417-20. PubMed ID: 17924444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.
    Liu HT; Kuo HC
    Urology; 2008 Jul; 72(1):104-8; discussion 108. PubMed ID: 18400272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
    Kuo HC; Liu HT; Chancellor MB
    Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome.
    Silva-Ramos M; Silva I; Oliveira O; Ferreira S; Reis MJ; Oliveira JC; Correia-de-Sá P
    PLoS One; 2013; 8(5):e64696. PubMed ID: 23741373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders.
    Liu HT; Chen CY; Kuo HC
    J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.